Literature DB >> 32818452

Instrument Gauge and Type in Uveal Melanoma Fine Needle Biopsy: Implications for Diagnostic Yield and Molecular Prognostication.

Lindsay K Klofas1, Carley M Bogan2, Alice C Coogan3, Stephen J Schultenover3, Vivian L Weiss3, Anthony B Daniels4.   

Abstract

PURPOSE: To systematically evaluate and compare the effects of using small-gauge needles and vitrectors on the ability to obtain adequate diagnostic and prognostic uveal melanoma biopsy specimens.
DESIGN: Comparative evaluation of biopsy instruments.
METHODS: Survival of uveal melanoma cells was evaluated in vitro following needle aspiration. Five therapeutically enucleated eyes were sampled in triplicate for ex vivo diagnostic biopsy experiments with 25 gauge (25 G) needle, 27 gauge (27 G) needle, and 27 G vitrector. During surgery in 8 patients, paired diagnostic transscleral fine needle aspiration biopsies were performed using both 25 G and 27 G needles. A review of cytologic specimens was performed by a panel of 3 expert cytopathologists. A retrospective chart review was performed to evaluate 100 consecutive tumors undergoing prognostic biopsy for gene expression profiling to assess the relationship between needle gauge and prognostic adequacy.
RESULTS: No significant cell shearing of uveal melanoma cells occurred in vitro with 25 G, 27 G, or 30 G needles. For ex vivo biopsy samples, diagnostic yield was 100% using 25 G needle (5/5) or 27 G vitrector (5/5) but 60% using a 27 G needle (3/5). For in vivo samples, no difference in diagnostic yield was found between 25 G (75%, 6/8) or 27 G (75%, 6/8) needle sizes. Of 100 molecular prognostic biopsy samples evaluated, 65 were obtained using 27 G needles; for these biopsies, the prognostic yield was 65/65 (100%).
CONCLUSIONS: For diagnostic biopsy of uveal melanoma, a larger-gauge needle or a 27 G vitrector may have better overall cellularity and diagnostic yield when compared to a 27 G needle. However, for much more common molecular prognostic testing, a 27 G needle provided adequate sample in 100% (65/65) of cases, and a larger needle provided no additional benefit.
Copyright © 2020 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32818452      PMCID: PMC8117558          DOI: 10.1016/j.ajo.2020.08.014

Source DB:  PubMed          Journal:  Am J Ophthalmol        ISSN: 0002-9394            Impact factor:   5.258


  36 in total

1.  Quantitation of tumor seeding from fine needle aspiration of ocular melanomas.

Authors:  B J Glasgow; H H Brown; A M Zargoza; R Y Foos
Journal:  Am J Ophthalmol       Date:  1988-05-15       Impact factor: 5.258

2.  Transvitreal retino-choroidal biopsy of suspected malignant lesions of the choroid. Follow-up of cases over 7 years.

Authors:  O A Jensen; J U Prause; E Scherfig
Journal:  Acta Ophthalmol Scand       Date:  1997-08

3.  Transvitreal Retinochoroidal Biopsy Provides a Representative Sample From Choroidal Melanoma for Detection of Chromosome 3 Aberrations.

Authors:  Mette Bagger; Morten T Andersen; Steffen Heegaard; Mette K Andersen; Jens F Kiilgaard
Journal:  Invest Ophthalmol Vis Sci       Date:  2015-09       Impact factor: 4.799

4.  Prognostic biopsy of choroidal melanoma: an optimised surgical and laboratory approach.

Authors:  Martina Angi; Helen Kalirai; Azzam Taktak; Rumana Hussain; Carl Groenewald; Bertil E Damato; Heinrich Heimann; Sarah E Coupland
Journal:  Br J Ophthalmol       Date:  2017-06-08       Impact factor: 4.638

5.  Prognostic implications of cytopathologic classification of melanocytic uveal tumors evaluated by fine-needle aspiration biopsy.

Authors:  James Jay Augsburger; Zélia Maria Corrêa; Nikolaos Trichopoulos
Journal:  Arq Bras Oftalmol       Date:  2013 Mar-Apr       Impact factor: 0.872

6.  Multi-year follow-up of fine-needle aspiration biopsy in choroidal melanoma.

Authors:  Tara A McCannel; Melinda Y Chang; Barry L Burgess
Journal:  Ophthalmology       Date:  2012-01-09       Impact factor: 12.079

7.  Collaborative Ocular Oncology Group report number 1: prospective validation of a multi-gene prognostic assay in uveal melanoma.

Authors:  Michael D Onken; Lori A Worley; Devron H Char; James J Augsburger; Zelia M Correa; Eric Nudleman; Thomas M Aaberg; Michael M Altaweel; David S Bardenstein; Paul T Finger; Brenda L Gallie; George J Harocopos; Peter G Hovland; Hugh D McGowan; Tatyana Milman; Prithvi Mruthyunjaya; E Rand Simpson; Morton E Smith; David J Wilson; William J Wirostko; J William Harbour
Journal:  Ophthalmology       Date:  2012-04-21       Impact factor: 12.079

8.  Clinical presentation, pathological features and natural course of metastatic uveal melanoma, an orphan and commonly fatal disease.

Authors:  Linda Cerbone; Rita Van Ginderdeuren; Joost Van den Oord; Steffen Fieuws; Werner Spileers; Liza Van Eenoo; Agnieszka Wozniak; Cora N Sternberg; Patrick Schöffski
Journal:  Oncology       Date:  2014-04-23       Impact factor: 2.935

9.  Ultrasonically guided needle biopsy and cytologic diagnosis of solid intraocular tumors.

Authors:  F A Jakobiec; D J Coleman; A Chattock; M Smith
Journal:  Ophthalmology       Date:  1979-09       Impact factor: 12.079

10.  Primary Choroidal Lymphoma Diagnosed with 27-Gauge Pars Plana Vitrectomy Choroidal Biopsy.

Authors:  Andrew W Kam; Justin Galvin; Svetlana Cherepanoff; A Andrew Miller; Adrian T Fung
Journal:  Case Rep Ophthalmol       Date:  2019-07-23
View more
  2 in total

1.  Integrative analysis identifies key genes related to metastasis and a robust gene-based prognostic signature in uveal melanoma.

Authors:  Shizhen Lei; Yi Zhang
Journal:  BMC Med Genomics       Date:  2022-03-17       Impact factor: 3.063

2.  Uveal melanoma patient attitudes towards prognostic testing using gene expression profiling.

Authors:  Basil K Williams; Jennifer J Siegel; Katherina M Alsina; Lauren Johnston; Amanda Sisco; Kyleigh LiPira; Sara M Selig; Peter G Hovland
Journal:  Melanoma Manag       Date:  2022-09-16
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.